June 6th 2023
Ocular Therapeutix is scheduled to present trial results as well as participate in a panel discussion and sponsor a presentation at the 2023 Clinical Trials at the Summit Annual Meeting.
June 3rd 2023
Cases and Conversations™: New Treatment Strategies for nAMD & DME
(CME Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium
(COPE Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium
(CME/CNE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases
(COPE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases
C.R.U. Eye Symposium (Current, Relevant, Useful)
(CME Credit) Community Practice Connections™: Expert Approaches in Cataract Surgery – Managing Advances in Techniques and Technologies With an Updated Armamentarium
(COPE Credit) Community Practice Connections™: Expert Approaches in Cataract Surgery – Managing Advances in Techniques and Technologies With an Updated Armamentarium
The European Society of Ophthalmology's (SOE) focus on young ophthalmologistsJune 1st 2023
SOE holds a special place in its heart for the up-and-coming young ophthalmologists and is providing them a number of opportunities to hone their skills and establish professional contacts at this meeting.
Roche Canada completes negotiations with the pCPA for VABYSMO® to treat wet AMD and DMEMay 30th 2023
VABYSMO is the first treatment for wet AMD and DME in Canada that acts by targeting both VEGF-A and Ang-2, two key drivers of vascular instability that have been associated with vision-threatening retinal conditions.
Researchers find experimental drug may prevent or slow vision loss in people with diabetesMay 30th 2023
Results of the study, published in the Journal of Clinical Investigation, showed evidence that an experimental drug called 32-134D may prevent or slow vision loss in people with diabetes.
Oxurion NV enrolls 108 patients in KALAHARI Phase 2, Part B clinical trial for diabetic macular edemaMay 30th 2023
Oxurion NV has reached its enrollment target of 108 patients in its KALAHARI Phase 2, Part B clinical trial for diabetic macular edema (DME) and will likely continue to include additional participants in the trial due to high interest.
Annexon announces topline results from ARCHER Phase 2 trial of ANX007 for geographic atrophy (GA)May 26th 2023
Data supports ANX007 as the first complement therapy to preserve visual acuity, achieving statistically significant protection, but reduction in rate of geographic atrophy lesion growth did not reach statistical significance.
iHealthScreen Inc. applies for FDA 510K Submission for iPredict™, an AI-based, software as a medical device tool to diagnosis AMDMay 24th 2023
The iPredictTM AI Eye Screening System will provide a fully automated age-related macular degeneration (AMD) screening report in less than 60 seconds.
The Korean MFDS grants IND approval for PharmAbcine’s phase I clinical trial of its novel TIE2 agonistic antibody in nAMDMay 24th 2023
PMC-403 is a first-in-class antibody that activates TIE2, a receptor specifically expressed in vascular endothelial cells. The clinical trial will take place in multiple hospitals in South Korea.
Research provides evidence for protein deletion in age and diabetes related retinal diseasesMay 24th 2023
The research conducted at the Wayne State University School of Medicine implies that VCAM1 antagonism could be a promising therapeutic strategy for proliferative retinal disorders.
Phase 2 study of ABVC BioPharma Vitargus® receives ethical approval at Sydney Eye Hospital in AustraliaMay 23rd 2023
Early clinical studies indicate that Vitargus® has unique properties that could eliminate the need for patients to remain face-down after retinal detachment and vitreous hemorrhage surgery.
Ophthalmologists on front lines of identifying victims of intimate partner violence through ocular traumaMay 23rd 2023
Alik and colleagues noted "45% of IPV injuries involve the eyes. Many medical fields have increased IPV-related research; however, ophthalmology IPV research remains rare.”
Oculis reveals positive top line results for OCS-01 eye drops to treat DME during Stage 1 of its Phase 3 DIAMOND trialMay 22nd 2023
DIAMOND is a Phase 3, two-stage, double-masked, randomized, multi-center trial to assess the efficacy and safety of OCS-01 eye drops in DME patients. The primary objective of Stage 1 was to select the optimal dosing regimen.